Evidence map›Paper›PMID 34644706›Full record

Trial reportKidney & blood pressure research2021

The Predialysis Serum Sodium Level Modifies the Effect of Hemodialysis Frequency on Left-Ventricular Mass: The Frequent Hemodialysis Network Trials.

Jochen G Raimann, Christopher T Chan, John T Daugirdas, Thomas Depner, Tom Greene, George A Kaysen, Alan S Kliger, Peter Kotanko, Brett Larive, Gerald Beck and 5 more

Erratum issuedOpen access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Kidney & blood pressure research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 2 countries.

Jochen G RaimannRenal Research Institute, New York, New York, USA.
Christopher T ChanUniversity Health Network Toronto, Toronto, Ontario, Canada.
John T DaugirdasUniversity of Illinois College of Medicine, Chicago, Illinois, USA.
Thomas DepnerUniversity of California Davis, Davis, California, USA.
Tom GreeneUniversity of Utah, Salt Lake City, Utah, USA.
George A KaysenUniversity of California Davis, Davis, California, USA.
Alan S KligerYale New Haven Health System, New Haven, Connecticut, USA.
Peter KotankoRenal Research Institute, New York, New York, USA.
Brett LariveCleveland Clinic Foundation, Cleveland, Ohio, USA.
Gerald BeckCleveland Clinic Foundation, Cleveland, Ohio, USA.
Robert McGregor LindsayWestern University, London, Ontario, Canada.
Michael V RoccoWake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Glenn M ChertowStanford University School of Medicine, Stanford, California, USA.
Nathan W LevinRenal Research Institute, New York, New York, USA.
Frequent Hemodialysis Network (FHN) Trial Group
Cleveland Clinic · USMount Sinai Health System · USUniversity of California, Davis · USIllinois College · USRenal Research Institute · USStanford University · USUniversity Health Network · CAUniversity of Utah · USWake Forest University · USWestern University · CAYale New Haven Health System · US

Funding

Clinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5M
Frequent Hemodialysis Network Data Coordinating CenterU01DK066597 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI BECK, GERALD J · 2003 to 2010
$8.9M
NCATS NIH HHS UL1 TR002548NIDDK NIH HHS U01 DK066597
6 · The paper itself

Abstract

introductionThe Frequent Hemodialysis Network (FHN) Daily and Nocturnal trials aimed to compare the effects of hemodialysis (HD) given 6 versus 3 times per week. More frequent in-center HD significantly reduced left-ventricular mass (LVM), with more pronounced effects in patients with low urine volumes. In this study, we aimed to explore another potential effect modifier: the predialysis serum sodium (SNa) and related proxies of plasma tonicity.

methodsUsing data from the FHN Daily and Nocturnal Trials, we compared the effects of frequent HD on LVM among patients stratified by SNa, dialysate-to-predialysis serum-sodium gradient (GNa), systolic and diastolic blood pressure, time-integrated sodium-adjusted fluid load (TIFL), and extracellular fluid volume estimated by bioelectrical impedance analysis.

resultsIn 197 enrolled subjects in the FHN Daily Trial, the treatment effect of frequent HD on ∆LVM was modified by SNa. When the FHN Daily Trial participants are divided into lower and higher predialysis SNa groups (less and greater than 138 mEq/L), the LVM reduction in the lower group was substantially higher (-28.0 [95% CI -40.5 to -15.4] g) than in the higher predialysis SNa group (-2.0 [95% CI -15.5 to 11.5] g). Accounting for GNa, TIFL also showed more pronounced effects among patients with higher GNa or higher TIFL. Results in the Nocturnal Trial were similar in direction and magnitude but did not reach statistical significance. DISCUSSION/

conclusionIn the FHN Daily Trial, the favorable effects of frequent HD on left-ventricular hypertrophy were more pronounced among patients with lower predialysis SNa and higher GNa and TIFL. Whether these metrics can be used to identify patients most likely to benefit from frequent HD or other dialytic or nondialytic interventions remains to be determined. Prospective, adequately powered studies studying the effect of GNa reduction on mortality and hospitalization are needed.

Indexed as

Renal DialysisAdultAgedBlood PressureFemaleHumansHypertrophy, Left VentricularKidney Failure, ChronicMaleMiddle AgedSodiumSodiumBlood pressureEffect modificationFluid overloadFrequent hemodialysisLeft-ventricular mass

Identifiers

PMID34644706
PMCPMC8678184
OpenAlexW3205798513

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.